Zymeworks ZYME
NASDAQ ZYME
$29.19 -0.71 (-2.37%)
As of: Sep 4, 2026 · 3:59 PM EDT

Zymeworks (ZYME) Amortization of Deferred Charges (2026)

Zymeworks (ZYME) posted Amortization of Deferred Charges of $26000.0 for Q1 2026, down 97.19% sequentially from $924000.0 in Q4 2025, and down 96.32% YoY from $707000.0 in Q1 2025.

Analysis

Zymeworks (ZYME) Amortization of Deferred Charges (2026) Analysis & Trends

Zymeworks has reported Amortization of Deferred Charges for 6 years, with the latest figure at $26000.0 in Q1 2026.

  • Quarterly Amortization of Deferred Charges fell 96.32% year-over-year to $26000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.7 million (up 1.39% YoY) and the FY2025 annual result came in at $3.4 million, up 34.91% from the prior year.
  • Amortization of Deferred Charges declined to $26000.0 in Q1 2026 per ZYME's latest filing, from $924000.0 in the prior quarter.
  • Over five years, Amortization of Deferred Charges peaked at $3.5 million in Q3 2023 and troughed at $26000.0 in Q1 2026.
  • A 5-year average of $1.0 million and a median of $690000.0 in 2024 frame the typical range for Amortization of Deferred Charges.
  • The sharpest annual moves came in 2023 and 2026: Amortization of Deferred Charges surged 440.03% in 2023, then sank 96.32% in 2026.
  • Over 5 years, Amortization of Deferred Charges stood at $627000.0 in 2022, then soared by 81.66% to $1.1 million in 2023, then plunged by 39.42% to $690000.0 in 2024, then soared by 33.91% to $924000.0 in 2025, then tumbled by 97.19% to $26000.0 in 2026.
  • According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $26000.0, $924000.0, and $1.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Zymeworks 2.13 Bn 1.86 Bn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 87,000.00
Mar 31, 2026 26,000.00